I-07 Claire Li Clinical trial simulations of the anticancer agents- abiraterone and nilotinib Wednesday 10:15-11:45 |
I-23 Maria Matoses Osborne Development of a PBPK model for the anticancer drug Vivia009 and its main metabolite administered as a new delivery system in the Rat Wednesday 10:15-11:45 |
I-25 Christophe Meille Modified model of drug induced thrombocytopenia efficiently projects safe starting dose in human from preclinical data Wednesday 10:15-11:45 |
I-45 Zinnia Parra-Guillen Tumour Growth Modelling In Immunotherapy Wednesday 10:15-11:45 |
I-46 Mélanie Pastor Modeling of the effect of G-CSF in limiting the neutropenic toxicity of carboplatin Wednesday 10:15-11:45 |
I-58 Sylvie Retout Prediction of occurrence of thrombocytopenia to select Phase 1b dose and dosing regimen for a selective inhibitor of p53-MDM2 in patients with solid tumors Wednesday 10:15-11:45 |
I-59 Benjamin Ribba A model for low-grade glioma tumor growth and response to chemotherapy and radiotherapy Wednesday 10:15-11:45 |
I-66 Hauke Ruehs Integrated PK/PD model for oxaliplatin in different human matrices Wednesday 10:15-11:45 |
II-05 Maria Luisa Sardu Biomarker-driven Models of Tumour Growth Inhibition in preclinical animal studies Wednesday 15:10-16:40 |
II-07 Emilie Schindler PKPD-Modeling of Standard Uptake Value (SUV) in Gastro-Intestinal Stromal Tumors (GIST) patients treated with sunitinib Wednesday 15:10-16:40 |
II-43 Coen van Hasselt Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab Wednesday 15:10-16:40 |
II-58 Shelby Wilson The Enhancement of Tumor Vaccine Efficacy by Immunotherapy Wednesday 15:10-16:40 |
II-59 Gudrun Wuerthwein Population Pharmacokinetics of caspofungin in a phase II dose escalation study Wednesday 15:10-16:40 |
II-60 Wenyuan Xiong Pharmacokinetic interspecies extrapolation of a fully human mAb from animal to human Wednesday 15:10-16:40 |
II-63 Jianping Zhang Population Analysis of Tumor Growth Inhibition and Progression-Free Survival Following Lapatinib Treatment in Patients with Advanced/Metastatic Breast Cancer Wednesday 15:10-16:40 |
III-03 Azucena Aldaz Capecitabine: a pharmacokinetic model derived from its clinical use Thursday 10:05-11:35 |
III-06 Orna Amir Mechanistic NSCLC vascular tumor model: insights to prognosis towards personalized medicine Thursday 10:05-11:35 |
III-12 Gaurav Bajaj Model-based analysis of disease progression in pancreatic cancer based on registry data collected from the Surveillance, Epidemiology, and End Result (SEER) database Thursday 10:05-11:35 |
III-14 Brendan Bender A multicompartmental population PK model elucidating the complex disposition of trastuzumab emtansine (T-DM1): an antibody-drug conjugate for the treatment of HER2-positive cancer Thursday 10:05-11:35 |
III-31 Núria Buil Bruna Modeling evaluation of different in vitro experimental designs to characterise antitumor drug effect Thursday 10:05-11:35 |
III-35 Quentin Chalret du Rieu Semi-mechanistic thrombocytopenia model of a new histone deacetylase inhibitor (HDACi) in development, with a drug-induced apoptosis of megakaryocytes. Thursday 10:05-11:35 |
III-43 Laurent Claret Evaluation of Tumor-Size Response Metrics to Predict Survival and Progression Free Survival in First-Line Metastatic Colorectal Cancer Thursday 10:05-11:35 |
III-46 Damien Cronier Population Pharmacokinetic Study of a New Humanized Anti-CD20 Monoclonal Antibody AME-133v (LY2469298) in Patients with Previously Treated Folicular Lymphoma. Thursday 10:05-11:35 |
III-48 Elyes Dahmane The influence of CYP2D6 genetic polymorphism on tamoxifen and its active metabolite exposure in breast cancer patients: preliminary results from a prospective, open-label trial. Thursday 10:05-11:35 |
III-68 Eric Fernandez A database of PK-PD parameters and information for the modelling of anti-cancer drug regimen and combinations Thursday 10:05-11:35 |
IV-05 Lena Friberg Myelosuppression as a Biomarker of Tumor Response in Docetaxel Treated Metastatic Breast Cancer Patients Thursday 15:00-16:30 |
IV-15 Pascal Girard Simultaneous Ocular Adverse Event and Treatment Discontinuation Model of Pimasertib Thursday 15:00-16:30 |
IV-21 Verena Gotta Probability of achieving optimal molecular response to imatinib in chronic myeloid leukemia (CML) patients: Pharmacokinetic/Pharmacodynamic (PK/PD) relationships observed under field-conditions Thursday 15:00-16:30 |
IV-26 Ivelina Gueorguieva Development Of Integrated Pharmacokinetic/Pharmacodynamic (PK/PD) Model For The Novel TGF- β Inhibitor LY2157299 Monohydrate: Preclinical To Phase II Thursday 15:00-16:30 |
IV-28 Emma Hansson PKPD Modeling of Predictors for Side Effects and Overall Survival in Patients with Gastro Intestinal Stromal Tumor Treated with Sunitinib Thursday 15:00-16:30 |
IV-31 Tomi Hendrayana Population pharmacokinetic (PK) model for fluorouracil (5-FU) accounting for irregularities in infusion rate Thursday 15:00-16:30 |
IV-32 Emilie Hénin A latent-variable model for Sorafenib-induced Hand-Foot Syndrome (HFS) in non-selected patients to predict toxicity kinetics according to sorafenib administrations Thursday 15:00-16:30 |
IV-49 Amita Joshi A physiologically-based pharmacokinetic (PBPK) approach to evaluate differences in pharmacokinetics between healthy subjects and cancer patients Thursday 15:00-16:30 |
IV-51 Friederike Kanefendt Modeling Sunitinib and Biomarker Response as potential Predictors of Time to Progression in Patients with Metastatic Colorectal Cancer Thursday 15:00-16:30 |
IV-63 Steve Kuan Population Pharmacokinetic (PK) Modelling of Bortezomib After Bolus Intravenous Injection in Cancer Patients Thursday 15:00-16:30 |